Our example comes from a recent systematic review (SR) and NMA of therapies forpreviously untreated advanced BRAF-mutated melanoma.60 We chose this example as it represents a clinical area in which non-PH iscommonly encountered and the structure of the network, many treatment options withlimited direct head-to-head evidence, represents a commonly encountered situation inHTA appraisals. The gene discussed is BRAF; the disease is melanoma.